|
Significant accounting policies (Detail Textuals) (USD $)
|
12 Months Ended | 12 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2013
Common stock
|
Dec. 31, 2012
Common stock
|
Dec. 31, 2011
Common stock
|
Dec. 31, 2010
Common stock
|
Apr. 06, 2010
Common stock
|
Dec. 31, 2013
Stock Options
|
Dec. 31, 2012
Stock Options
|
Dec. 31, 2011
Stock Options
|
Dec. 31, 2013
Warrants
|
Dec. 31, 2012
Warrants
|
Dec. 31, 2011
Warrants
|
|
| Significant Accounting Policies [Line Items] | ||||||||||||||
| Net proceeds from short term financing | $ 8,575,000 | |||||||||||||
| Prototype drug product | $ 250,000 | |||||||||||||
| Number of shares outstanding for issue from the Trust | 1,743,750 | |||||||||||||
| Antidilutive securities excluded from computation of earnings per share | 28,104,009 | 4,380,000 | 650,000 | 28,104,009 | 4,380,000 | 650,000 | ||||||||